Athena Athena

X
[{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"$553.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Buys a Majority Stake In mAbxience","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS\u00ae (bevacizumab-maly)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Mabxience","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Continues Its Expansion in Oncology with The Launch of Alymsys\u00ae (Bevacizumab) in 21 Countries Across Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"$553.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Completes Majority Stake Acquisition Of mAbxience Holding S.L., Significantly Enhancing Presence in High-Growth Biopharmaceuticals Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Mabxience","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Mabxience","sponsor":"Biosidus S.A.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Mabxience

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Through the agreement, mAbxience will be responsible for the manufacture of the active ingredient, developed by Biosidus as a biosimilar of Fabrazyme (agalsidase beta), which will be used for the treatment of Fabry disease.

            Lead Product(s): Agalsidase Beta

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biosidus S.A.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 05, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of agreement, mAbxience will fully develop the biosimilar, Denosumab (ref Prolia and XGEVA) and manufacture in it's GMP-approved facilities, while Amneal will guide the product through regulatory approval and have exclusive commercialization rights in the US.

            Lead Product(s): Denosumab

            Therapeutic Area: Musculoskeletal Product Name: MB-09

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amneal Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Abbott Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical market.

            Lead Product(s): Rituximab

            Therapeutic Area: Oncology Product Name: Novex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fresenius Kabi AG

            Deal Size: $553.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition August 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            U.S.FDA has approved Company’s Biologics License Application for bevacizumab-maly, is a vascular endothelial growth factor inhibitor, a biosimilar referencing Avastin for first or second-line treatment metastatic colorectal cancer.

            Lead Product(s): Bevacizumab

            Therapeutic Area: Oncology Product Name: Alymsys

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amneal Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical market.

            Lead Product(s): Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride

            Therapeutic Area: Oncology Product Name: Novex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fresenius Kabi AG

            Deal Size: $553.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.

            Lead Product(s): Bevacizumab-maly,Fluorouracil,Calcium Folinate

            Therapeutic Area: Oncology Product Name: Alymsys

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Zentiva

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY